approach has potential to treat a range of chronic and acute inflammatory disorders including ones that would otherwise be difficult to treat. Alivio has exclusive rights to a proprietary inflammation-targeting technology, based on the research of Dr. Karp (BWH/HMS) and Dr. Robert Langer (MIT), which is the first technology to reproducibly show the ability to target immunomodulatory compounds to inflamed tissue, which can lead to dramatic improvements in treatment efficacy with major reductions in systemic effects. The platform has been validated in multiple labs and preclinical models of inflammation, including models where the inflammation occurred in different parts of the body (e.g., the GI system, the bladder, joints, skin, etc.). The technology could potentially be used with a variety of medications (e.g., small molecules, biologics, and nucleic acids) both independently or in combination, and is designed to be administered orally or via other routes. With this platform, Alivio aims to address the dozens of conditions where inflammation is a central part of the underlying disease pathology, but where targeted and effective treatment options are lacking.